Ly03012, a class 1 new chemical drug, has entered phase I clinical trials

September 3, 2018 / Meitong news agency / -- LVYE Pharmaceutical Group announced that its new compounds under research and ly03012 sustained-release tablets, a class 1 chemical new drug in China, have been approved by the State Drug Administration to carry out phase I clinical trials Ly03012 is a new analgesic drug under development Recently, green leaf pharmaceutical's product line under research has received good news frequently Whether it's the clinical progress of new biological antibody drugs or the promotion of the next generation drugs in the field of tumor immunotherapy jointly developed with a number of global leading biotechnology companies, it all reflects the overall planning and far-reaching layout of green leaf pharmaceutical in the follow-up global product pipeline Ly03012, approved to enter phase I clinical trial, is one of the drugs under research of LVYE pharmaceutical in the field of analgesia It is a small molecule compound that is taken orally As a new inhibitor of monoamine neurotransmitter transporter, ly03012 can enter the brain and inhibit presynaptic membrane 5-hydroxytryptamine transporter (SERT), noradrenaline transporter (net) and dopamine transporter, DAT) to increase the concentration of norepinephrine, 5-hydroxytryptamine and dopamine in the synaptic space, and then play an analgesic role by enhancing the downward inhibition pathway of pain regulation In addition, ly03012 can also regulate the sleep wake of the body, which is different from the drugs in the same indication field that have been listed, and it can play an analgesic role without causing central inhibition related adverse reactions such as sedation and drowsiness LVYE believes that no matter in China or in the world's major pharmaceutical markets, analgesics will have an optimistic market prospect and growth potential According to the third-party iqvia (original IMS) data, the total sales volume of analgesic drugs in the U.S and European markets reached 17.946 billion US dollars in 2017, and the total sales volume of analgesic drugs in China was 11.473 billion yuan in 2017 National markets have maintained double-digit sales growth over the past two years At present, LVYE pharmaceutical has applied for compound patent, crystal patent and sustained-release tablet patent for ly03012 Among them, compound and crystal type patents have been obtained in China, the United States, Europe, Japan, South Korea and other countries The indications of ly03012 were diabetic peripheral neuralgia, fibromyalgia and osteoarthritis In addition to the Chinese market, LVYE is also committed to the simultaneous registration and marketing of the drug in the United States, Europe, Japan and other countries In addition to ly03012, LVYE pharmaceutical also has fentanyl patch, buprenorphine patch and other products in the field of analgesia At present, buprenorphine patch localization production and application in China has been in an orderly progress "Ly03012 will enrich and expand our product line in the field of analgesia, and continue to promote the development of the company in the field of analgesia." "At present, the company's existing drugs under research have gradually entered the harvest period," said the management of LVYE Pharmaceutical Group We hope to continue to increase investment in innovative drug research and development, and make a comprehensive layout of follow-up product pipelines, so as to lay a solid foundation for the company's deep development in the global market "